RAD51C germline pathogenic in breast: moderate-risk allele (~RR 2-4 for RAD51C/D, less es...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RAD51C-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | RAD51C germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IIB |
| Recommended combinations | standard breast therapy, PARPi off-label (HRD-positive context) |
| Evidence summary | RAD51C germline pathogenic in breast: moderate-risk allele (~RR 2-4 for RAD51C/D, less established for RAD51B). No PARPi label; off-label consideration in HRD context. ESCAT IIB-IIIA / OncoKB Level 3B. |
Notes
Cascade testing per NCCN. Enhanced screening recommended.
Used By
No reverse references found in the YAML corpus.